🇺🇸 FDA
Pipeline program

Bion 1301/FUB523

CFUB523A12201

Phase 2 small_molecule active

Quick answer

Bion 1301/FUB523 for IgA nephropathy is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Ophthalmics Europe
Indication
IgA nephropathy
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials